All In Biotech

Drug Trial Radar · NCT05060887

Immunogenicity and Safety of Three Dose Levels of OVX836 Candidate Vaccine Against Influenza in Healthy Volunteers.

Phase 2a, Single Center, Randomized, Double-blind, Controlled Study to Evaluate the Immunogenicity and the Safety of One Single Administration of OVX836 Influenza Vaccine at Two Dose Levels (300μg and 480μg) Given Intramuscularly (IM), in Comparison to OVX836 Influenza Vaccine at 180μg and Placebo Given IM in Healthy Subjects Aged 18-55 Years and in Healthy Subjects Aged 65 Years and Older.

Last checked: Nov 19, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 239 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

239

Actual

Start

Nov 15, 2021

Primary completion

Feb 1, 2022

Study completion Dec 7, 2022

Sponsor

Lead sponsor
OsivaxIndustry
Sponsor type
Industry
Collaborators
University Ghent
First posted
Sep 29, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This Phase 2a clinical trial is designed to evaluate the immunogenicity and the safety of one administration of OVX836 influenza vaccine at different dose levels (180µg, 300μg and 480μg) in order to assess the dose response of the OVX836 influenza vaccine.

Conditions

  • Influenza

Interventions

  • OVX836-003Biological

    One single administration intramuscularly at Day 1.

  • Saline solutionBiological

    One single administration intramuscularly at Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change of NP-specific T-cell frequencies in peripheral blood, measured by IFNγ ELISPOT, at Day 8 versus pre-injection baseline (Day 1).Time frame: at Day 8 versus pre-injection baseline (Day 1)
  2. Proportion of subjects reporting solicited local (Injection site redness, Injection site swelling, Injection site pain) and systemic symptoms (Fatigue, Headache, Arthralgia, Malaise, Myalgia, Fever)Time frame: during 7 days after vaccine administration
  3. Proportion of subjects reporting unsolicited Adverse EventsTime frame: during 29 days after vaccine administration
  4. Proportion of subjects with Influenza-Like-Illness cases associated with laboratory-confirmed influenzaTime frame: during the whole study duration, 180 days
  5. Severity scores of Influenza-Like-Illness cases (as per Flu-PRO® questionnaire)Time frame: during the whole study duration, 180 days
  6. Proportion of subjects reporting Serious Adverse EventsTime frame: during the whole study duration, 180 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Vaccinology (CEVAC)

    Ghent, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.